EROAD posts $144.2m H1 loss on charge below EBITDA as cash flow lifts

EROAD posted a net loss of $144.2m versus a $1.5m loss in HY25, and a pre-tax loss of $136.6m versus a $0.1m loss prior. Total equity contracted to $186.8m from $311.8m, a fall of roughly $125m broadly consistent with a non-cash charge sitting between EBITDA and PBT.

Above that line the result was steady-to-positive. Revenue rose 3.3% to $99.1m, EBITDA was effectively flat at $28.7m versus $29.2m, operating cash flow climbed to $25.7m from $17.3m, free cash flow improved to $5.1m from $0.1m, and net debt fell to $7.7m from $57.1m, taking leverage to 0.3x EBITDA from 2.0x.

EBITDA changed by less than $0.5m, but PBT deteriorated by roughly $136m. That gap implies an impairment, write-down, or other one-off of well over $100m sitting in depreciation, amortisation or impairment lines. The supplied excerpts do not name the charge, so on the read available the reported loss is almost entirely a carrying-value question, not an operating-performance question.

Cash quality genuinely strengthened. Cash conversion (OCF/EBITDA) lifted to 89.5% from 59.2%, and FCF grew to $5.1m. Receivable days were broadly stable at 65 versus 63, so the OCF improvement is not flattered by debtor stretching. This matters because it shows the recurring engine is producing cash even as the accounting result collapses.

The balance sheet was materially de-risked. Gross borrowings fell to $23.2m from $68.4m and cash rose to $15.5m, leaving net debt at $7.7m. That gives EROAD funding flexibility for the ANZ expansion management has signalled, even with capex stepping up to 12.5% of revenue from 9.5%.

Historical shape is roughly even: HY25 was 49.3% of FY25 revenue and 49.0% of FY25 EBITDA, so annualised HY26 revenue of about $198.2m sits near the $194.4m FY25 base. NPAT shape is uninformative this period because the impairment-style charge dwarfs any normal H1/H2 split.

The release supports a read of mid-single-digit top-line growth and stable EBITDA margins; it does not support a clean read on full-year profit until the nature and recurrence of the below-EBITDA charge are clarified.

Cash conversion of 89.5% is materially better than the 59.2% prior, and FCF improvement is funded by genuine operating cash, not by stretching debtors or starving capex — capex actually rose 36.3% to $12.4m. Leverage at 0.3x EBITDA is a real structural improvement.

The reported NPAT and PBT, by contrast, are dominated by a non-cash item that is not explained in the supplied excerpts. ROE of -77.2% versus -0.5% is a direct consequence and is not informative about underlying returns. Until the charge is disclosed in detail, an investor should treat headline NPAT as accounting noise around an EBITDA line that was approximately flat. The Corporate & Development segment result also deteriorated to -$19.7m from -$17.4m, which warrants attention separately from any one-off.

This briefing cannot assess the composition of the below-EBITDA charge because the supplied excerpts do not disclose its line-item make-up.